As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
8 Analysts have issued a Spruce Biosciences Inc forecast:
8 Analysts have issued a Spruce Biosciences Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 1.30 1.30 |
86%
86%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -51 -51 |
7%
7%
|
|
| EBIT (Operating Income) EBIT | -51 -51 |
7%
7%
|
|
| Net Profit | -48 -48 |
12%
12%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
| Head office | United States |
| CEO | Javier Szwarcberg |
| Employees | 9 |
| Founded | 2014 |
| Website | sprucebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


